Ro CEO Zach Reitano: The case for GLP-1s | Rapid Response
About Zach
- Founder and CEO of Ro; built nationwide telemedicine, pharmacy and labs platform
- Grew Ro from 1-condition telehealth start-up to care for millions since 2017
- Ro valued at $7B in 2024 amid the GLP-1 boom
- Named to Fortune 40 Under 40
- Also honored by Forbes 30 Under 30, Inc. 30 Under 30, BI 30 Under 40
| 27:38
On this episode of Rapid Response, Ro CEO Zach Reitano joins the show to talk about what happens when a breakout drug becomes a full-blown market force. Since first appearing at the height of the Ozempic-Wegovy-Zepbound boom, Reitano has helped scale Ro into a leading provider of branded GLP-1s — grabbing headlines with a Super Bowl ad featuring Serena Williams and landing a major partnership with Novo Nordisk for the new pill version of Wegovy. He also takes on the tougher questions: the long-term health unknowns, the cultural backlash to “Ozempic face,” and what this wave of disruption could mean not just for pharma, but for the future of healthcare.
Related Episode
